197 related articles for article (PubMed ID: 33067480)
1. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma.
Haddad AF; Chen JS; Oh T; Pereira MP; Joshi RS; Aghi MK
Sci Rep; 2020 Oct; 10(1):17580. PubMed ID: 33067480
[TBL] [Abstract][Full Text] [Related]
2. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
4. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
[TBL] [Abstract][Full Text] [Related]
5. The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival.
Zhang J; Caruso FP; Sa JK; Justesen S; Nam DH; Sims P; Ceccarelli M; Lasorella A; Iavarone A
Commun Biol; 2019; 2():135. PubMed ID: 31044160
[TBL] [Abstract][Full Text] [Related]
6. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
7. A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.
Huang R; Lu X; Sun X; Wu H
Int J Immunopathol Pharmacol; 2024; 38():3946320241249395. PubMed ID: 38687369
[No Abstract] [Full Text] [Related]
8. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
9. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
10. RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.
Bagley SJ; Hwang WT; Brem S; Linette GP; O'Rourke DM; Desai AS
J Neurooncol; 2019 Jan; 141(1):95-102. PubMed ID: 30353265
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
[TBL] [Abstract][Full Text] [Related]
12. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
13. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of HLA-II related to LAG-3
Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
[TBL] [Abstract][Full Text] [Related]
15. The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.
Roufas C; Chasiotis D; Makris A; Efstathiades C; Dimopoulos C; Zaravinos A
Front Oncol; 2018; 8():27. PubMed ID: 29515971
[TBL] [Abstract][Full Text] [Related]
16. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
Zhang B; Shen R; Cheng S; Feng L
Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
[TBL] [Abstract][Full Text] [Related]
17. Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Dubinski D; Won SY; Rauch M; Behmanesh B; Ngassam LDC; Baumgarten P; Senft C; Harter PN; Bernstock JD; Freiman TM; Seifert V; Gessler F
Front Immunol; 2021; 12():627650. PubMed ID: 33868245
[TBL] [Abstract][Full Text] [Related]
18. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
Liu Y; Song C; Shen F; Zhang J; Song SW
PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
[TBL] [Abstract][Full Text] [Related]
19.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
20. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
